Our Team

Matt has been a healthcare-focused venture capital investor since 1980. He began his venture capital career with Citicorp Venture Capital, where he was VP and a member of the investment executive committee. Matt later joined Robertson, Stephens & Co. and was partner and Chairman of the Venture Capital Group. In 1991, he formed Mackowski & Shepler, an investment partnership focused on developing life science and medical technology companies and the predecessor to Telegraph Hill Partners (THP). Matt has represented THP on the boards of Kinetikos Medical (acquired by Integra), Ambion (acquired by Applied Biosystems), Aurora Discovery (acquired by NEXUS Biosystems), Interface Associates (acquired by NDC), Asuragen, Althea Technologies (acquired by Ajinomoto), AltheaDx, MedPricer, Magstim and TrakCel. Matt received a BA from Duke University and an MBA from The Wharton School.

Gary has worked in the healthcare and medical device industry since 1981. Gary began his career in healthcare with United States Surgical Corporation where he spent 22 years in roles of increasing responsibilities, including Vice President of Sales Operations and Distribution Sales for Tyco Healthcare following the acquisition of USS by Kendall. He next joined UTI Corporation as Executive Vice President of Sales and Marketing, where he led the sales and marketing strategy through the acquisition and integration of MedSource Technologies, the re-branding of the combined organization as Accellent, and its acquisition by Kohlberg, Kravis, and Roberts in 2005. Gary then joined Telegraph Hill Partner (THP) portfolio company Interface Catheter Solutions as President and CEO. He led the strategic growth into contract manufacturing through its acquisition by NDC/Confluent Medical in 2015. Most recently, Gary was President of Trelyst, a subsidiary of NuSil Technology LLC focused on developing silicone-based combination drug-delivery devices and through its merger with Avantor in 2016. Gary has represented THP on the boards of Argonaut Manufacturing Services, Dynex Technologies, InvisALERT and Medpricer (acquired by Premier). Gary holds a Bachelor of Science in Marketing from Millikin University.

Mike is an accomplished executive with over 25 years of broad-based managerial and financial experience in the healthcare industry, including expertise building high growth, dynamic companies. Mike began his career with PricewaterhouseCoopers where he spent 12 years prior to joining Sachs Group, a healthcare data and information company, as its chief financial officer (CFO). Upon the sale of Sachs Group, Mike again partnered with Michael Sachs to form Sg2, a healthcare analytics and intelligence company where Mike served as executive vice president and CFO until the Sg2 sale in 2014. Mike is currently vice chairman and CFO of TLSG Investments, LLC, an early-stage venture firm focused on technology-enabled healthcare services and SAAS-based software companies. He serves on several boards of TLSG Investments’ portfolio companies. Mike is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Northern Illinois University.

Dave is a veteran of the health care industry and is a seasoned CEO and founder. Prior to co-founding Emerging Therapy Solutions, Dave led several managed care technology companies, including Medication Management Systems, Inc. (acquired by Genoa HealthCare), NovoLogix (acquired by CVS), and RxHub. Previously, Dave was CEO of United Resource Networks at United Health Group, a business that managed organ and tissue transplants for 45 million payer lives, and SVP at American MedCenters, an HMO management company. Dave holds a BS in Pharmacy from Ohio State University and a Ph.D. from the University of Minnesota.

Ravi is a seasoned executive and founder with a strong background in finance and healthcare and clinical services. Prior to TrakCel, Ravi was the CFO of Biotec Services International and has extensive leadership experience in finance, health, biotech, safety, and environmental functions. Ravi has a BSc in Biochemistry and Molecular Biology from Cardiff University.

Kevin has extensive knowledge and experience in health care and health care transactions. His primary goal is to help small and medium sized health care companies grow successfully and maximize their value. Kevin has a law degree and an MBA from the University of Minnesota. His experience spans law, healthcare, and mergers and acquisitions, having participated in over 70 transactions.